Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$15.67 USD

15.67
8,845,931

+0.47 (3.09%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $15.63 -0.04 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

by Zacks Equity Research

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

Sweta Jaiswal, FRM headshot

How Are Genomics ETFs Responding to Q2 Earnings?

by Sweta Jaiswal, FRM

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -65.57% and -45.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $132.37, marking a -1.22% move from the previous day.

Sweta Jaiswal, FRM headshot

A Comprehensive Guide to Genomic ETFs

by Sweta Jaiswal, FRM

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

Ekta Bagri headshot

3 Biotech Stocks Poised to Gain in the Second Half of 2021

by Ekta Bagri

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

Zacks Equity Research

Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.

Sweta Jaiswal, FRM headshot

Genomics ETFs Surge on a Major Breakthrough in CRISPR Study

by Sweta Jaiswal, FRM

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.